Specialty pharmaceutical company Intelliject has received the US Food and Drug Administration(FDA)approval for its Auvi-Q(epinephrine injection,USP)used in the emergency treatment of life-threatening allergic reactions in people who are at risk or have a history of anaphylaxis.
According to Intellioject,Auvi-Q is the only compact auto-injector with audio and visual cues,which will guide patients and caregivers step-by-step through the injection process.
Intelliject chief science officer Eric Edwards said in developing Auvi-Q,the company's goal is to offer patients and caregivers an innovative treatment option that is easy to use in an emergency.
''Auvi-Q's small size and intuitive design,as well as its first-in-class prompt system that talks a user through the injection process,will help patients and caregivers manage a life-threatening allergic reaction,"Edwards added.
Auvi-Q contains epinephrine used to treat severe,life-threatening allergic reactions that may occur as a result of exposure to allergens,which include nuts,shellfish,dairy,eggs,insect bites,latex and medication and others.
Intelliject president and CEO Spencer Williamson said the FDA approval of Auvi-Q is an important milestone for the company and is a result of our steadfast commitment to developing patient-centric products.
"We are building on this approval and have a pipeline of drug/device combination products for select therapy areas,"Williamson added.
